title: Acute kidney injury after transarterial chemoembolization for hepatocellular carcinoma: a retrospective analysis.
abstract: BACKGROUND
  Transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) may result in acute kidney injury (AKI) like other angiographic interventions.
  
  
  METHODS
  To investigate the incidence, risk factor and outcomes of AKI after TACE, defined by Acute Kidney Injury Network (AKIN) criteria, we retrospectively analyzed 442 TACE treatment sessions in 236 HCC patients.
  
  
  RESULTS
  The incidence of AKI in the first 48 h after TACE was 9.8% (23 of 236 patients at risk). Presence of hypertension (OR 3.24, 95% CI 1.21-8.72, p = 0.02), lower baseline serum albumin (OR 0.29, 95% CI 0.15-0.56, p < 0.01) and higher creatinine level (OR 12.02, 95% CI 3.49-41.39, p < 0.01) were independent risk factors of AKI. Prolonged renal insufficiency after 1 month was observed in 24.1% of AKI episodes.
  
  
  CONCLUSIONS
  AKI is a common complication after TACE and we have to pay attention to the prevention and early recognition of AKI occurrence in high-risk patients.
authors.affiliation: Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
authors.forename: Jongha
authors.initials: J
authors.lastname: Park
authors.forename: Hyun Chul
authors.initials: HC
authors.lastname: Chung
authors.forename: Jong Soo
authors.initials: JS
authors.lastname: Lee
authors.forename: Byeong Man
authors.initials: BM
authors.lastname: Lee
authors.forename: Dong Min
authors.initials: DM
authors.lastname: Kim
authors.forename: Jae Cheol
authors.initials: JC
authors.lastname: Hwang
authors.forename: Min-Woo
authors.initials: MW
authors.lastname: Jo
authors.forename: Maengseok
authors.initials: M
authors.lastname: Noh
authors.forename: Jung Woo
authors.initials: JW
authors.lastname: Shin
mesh_terms: D000208:Acute Disease; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000503:physiopathology / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects*; D003404:Creatinine / Q000097:blood; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000209:etiology / Q000503:physiopathology; D015994:Incidence; D007668:Kidney / Q000293:injuries* / Q000503:physiopathology; D007674:Kidney Diseases / Q000097:blood / Q000209:etiology* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D012709:Serum Albumin / Q000032:analysis
chemical_list: D012709:Serum Albumin; D003404:Creatinine